

RPG LIFE SCIENCES LIMITED



Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.

CIN: L24232MH2007PLC169354;

Tel: +91-22-24981650; Fax: +91-22-24970127

E-mail: info@rpglifesciences.com; Web: www.rpglifesciences.com

PART I

(Rs. in lakhs)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30th JUNE, 2015

PARTICULARS	3 months ended			Year ended
	30.6.2015	31.3.2015	30.6.2014	31.3.2015
	Unaudited			Audited
1. Income from Operations				
(a) Net Sales/Income from Operations (Net of Excise Duty)	6,650	6,119	5,879	23,308
(b) Other Operating Income	94	557	79	919
Total Income from Operations (Net)	6,744	6,676	5,958	24,227
2. Expenses				
(a) Cost of Materials Consumed	1,311	1,222	1,526	5,920
(b) Purchases of Stock-in-Trade	777	505	516	2,378
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	290	389	233	171
(d) Employee Benefits Expense	1,777	1,730	1,561	6,866
(e) Depreciation and Amortisation Expense	255	304	226	1,136
(f) Provision for Doubtful Debts and Advances (Net)	16	63	9	(323)
(g) Other Expenses	2,038	1,921	1,765	7,798
Total Expenses	6,464	6,134	5,836	23,946
3. Profit/(Loss) from Operations before Other Income, Finance Costs and Exceptional Items	280	542	122	281
4. Other Income	28	-	30	91
5. Profit/(Loss) from Ordinary Activities before Finance Costs	308	542	152	372
6. Finance Costs	94	72	42	272
7. Profit / (Loss) from Ordinary Activities after Finance Costs but before Exceptional Items	214	470	110	100
8. Exceptional Items	-	-	-	-
9. Profit/(Loss) from Ordinary Activities before Tax	214	470	110	100
10. Tax Expense/(Credit) (including Deferred Tax)	-	-	(6)	-
- Earlier Year Tax	-	-	-	-
11. Net Profit/(Loss) for the period	214	470	116	100
12. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323
13. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)				11,193
14. Earnings/(Loss) per Share (of Rs. 8 each) (not annualised):				
(a) Basic	1.29	3.04	0.70	0.60
(b) Diluted	1.29	3.04	0.70	0.60

PART II

Select Information for the Quarter ended 30th June, 2015

PARTICULARS	3 months ended			Year ended
	30.6.2015	31.3.2015	30.6.2014	31.3.2015
A PARTICULARS OF SHAREHOLDING				
1. Public Shareholding				
- Number of Shares	5,492,188	5,591,135	6,321,501	5,591,135
- Percentage of Shareholding	33.21	33.81	38.23	33.81
2. Promoters and Promoter Group Shareholding				
(a) Pledged/Encumbered				
- Number of Shares	-	-	-	-
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-
- Percentage of Shares (as a % of the total Share Capital of the company)	-	-	-	-
(b) Non-Encumbered				
- Number of Shares	11,043,917	10,944,970	10,213,740	10,944,970
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total Share Capital of the company)	66.79	66.19	61.77	66.19

PARTICULARS	3 months ended
	30.06.2015
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	5
Disposed of during the quarter	5
Remaining unresolved during the quarter	-

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meetings held on 28th July, 2015.
- The results for the quarter ended 30th June, 2015 have been subjected to limited review by the statutory auditors of the Company.
- The Company is exclusively engaged in the pharmaceuticals segment.
- Figures for the prior periods have been regrouped where necessary.

For RPG Life Sciences Limited

CT. Renganathan
Managing Director

Mumbai, 28th July, 2015

